Загидуллин Н. Ш., Загидуллин Ш. З. Приверженность терапии статинами. Кардиоваскулярная терапия и профилактика. 2008;7(1):107-111.
1. Scandinavian Simvasthathin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvasthatin Survival Study (4S). Lancet 1994; 344: 1349–57.
2. The CARE Study Group (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001–9.
3. The LIPID Study Group. Long term effectiveness and safety of pravastatine in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379–87.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.
5. Tamargo J, Caballero R, Gomez R, et al. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology and Therapeutics 2007; 114: 107–26.
6. Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Pharmacol 2003; 59: 659–61.
7. Mann DM, Allegrante JP, Natarajan S, et al. Predictors of Adherence to Statins for Primary Prevention. Cardiovasc Drugs Ther 2007; 21: 311–6.
8. Kaplan RC, Bhalodkar NC, Brown EJ, et al. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipidlowering medications. Prev Med 2004; 39(6): 1249–55.
9. Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of Awareness of on-Treatment Patients About Prescribed Statins. Am J Manag Care 2005; 11: 670–4.
10. Thiebaud P, Patel BV, Pharm D, et al. The effect of Switching on Compliance and Persistance: The Case of of Statin Treatment. Am J Manag Care 2005; 11: 670–4.
11. Blackburn DF, Pharm D, Dobson R, et al. Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy. Pharmacotherapy 2005; 25(8): 1035–43.
12. Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta6blockers and angiotensin6converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21(6): 485–8.
13. Benner JS, Glynn RJ, Mogun H, et al. Long6term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61.
14. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229–33.
15. Gotto AM, Grundy SM. Lowering LDL Cholesterol. Circulation 1999; 99: e4.
16. Водяницкая Н.А., Абдуева Ф.М., Гудилин Т.Е., Дановская Е.В. Полугодовая приверженность к лечению больных, перенесших острый коронарный синдром без элевации сегмента ST. http://www.rql.kiev.ua/cardio_j/2007/2/vodyanitskaya.htm
17. Riesen WF, Darioli R, Noll G. Lipid6lowering therapy strategies for improvning comliance. Curr Med Res Opin 2004; 20(2): 165–79.
18. Marquez CE, Marinez C, et al. Therapeutic comliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998; 22: 79–84.
19. Schwed A, Fallab CI, Burnier M, et al. Electronic momnitoring of compliance to lipidlowering therapy to clinical practice. J Clin Pharmacol 1999; 39: 402–9.
20. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000; 20: 410–6.
21. Jones PH, Davidson MH, Stein EA, et al. for STELLAR study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
